A team of researchers at the University of Toronto trialled a new drug combination to treat paediatric patients with low grade glioma. They found a new combination to improve on the results we often see from standard care and treatment.
What are the findings?
The trial tested the combination of two inhibitor drugs, Dabrafenib and Trametinib. These drugs are designed to limit the effectiveness of the cell mutations that would lead to cancer growth.
When compared with the standard chemotherapy drugs (Carboplatin and Vincristine), the new combination produced clinically significant results with an improvement in the response rate of the cohort.
The study also saw prolonged progression-free survival, and limited the progression of the disease for those considered ‘advanced cancer patients’.
The study continues to recruit patients to determine safety data, and determine the optimal duration of the treatment. The team also hope to make this treatment globally accessible by aligning with the World Health Organizations standards for childhood cancer treatments.
A change in care like this, even for a small part of our community, would improve the lives of so many individuals. It could increase the chances people have to lead healthy and fulfilling lives.
To read the full study, click here.
Want to receive all the latest research straight to your inbox?
Sign-up our curated, jargon-free weekly research newsletter. Click here to fill out our contact form and select ‘research’ to opt into our research newsletter.
Get involved with research…
If you would like to use your experience and insight to support clinical research, consider signing up to be a PRIME advocate for brainstrust.
If you or someone you love is living with a brain tumour and have any questions around this latest news, or want to access support, give us a call on 01983 292 405 or email firstname.lastname@example.org. You can also visit our little brainstrust website which features support for children affected by brain tumour.